Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Representation of Women and People of Color in Clinical Trials is Crucial

photo

SPONSORED CONTENT -- (StatePoint) Cardiovascular diseases and stroke remain leading causes of death worldwide. As researchers work to find new treatments that have the potential to benefit patients, they say that more diversity is needed among participants in clinical trials to advance understanding of these conditions.

“Clinical trials are a cornerstone of medical research and healthcare innovation. They are essential to advancing medical science and ensuring patient safety, and often lead to the development of effective new treatment options. However, it is crucial that they include participants from diverse backgrounds, encompassing a wide range of lived experiences and living conditions, and representing diverse races, ethnicities, ages, genders, and sexual orientations, so that all communities can benefit from scientific advancements,” says Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI, Professor of Medicine in Cardiology and Population Health Science and Policy Professor in Cardiovascular Clinical Research and Outcomes Director of Interventional Cardiovascular Research and Clinical Trials Mount Sinai Health System.

According to research published in JAMA Network Open, women with atrial fibrillation, which is an irregular heart rhythm, face a higher risk of complications, like stroke, compared to men. The American Heart Association reports that cardiovascular disease prevalence remains highest among non-Hispanic Black females and non-Hispanic Black males. Experts believe such gaps in care are partially due to representation in clinical trials. Historically, women and people of color have been underrepresented in cardiovascular research, which has in recent decades, relied primarily on white male study participants.

One program in particular is helping to address gaps in heart disease treatment as the first clinical program to enroll nearly 50,000 patients across three trials. It’s actively recruiting women and members from diverse populations in an effort to ensure its results are inclusive, equitable and relevant for all patients.

The Librexia program is a phase 3 clinical trial investigating a potential new treatment for patients with blood clotting diseases, including acute coronary syndrome (i.e. heart attack), atrial fibrillation and prevention of repeated strokes. The program is designed to find treatment options that can potentially help improve outcomes in a wide range of patients, including underserved populations like women and people of color. To ensure that trial enrollment represents the individuals likely to take the medication, all who meet the criteria are encouraged to explore if the trials are a fit for them. A clinical trial helps advance research that may benefit family members, the community and future generations. To learn more about cardiovascular and stroke trials near you, visit researchincludesme.com.

“Diverse representation in clinical trials can help us better understand the benefits of a particular medication across all segments of the population,” says Dr. Mehran.

Photo Credit: (c) kate_sept2004 / iStock

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.